Hyperbaric Oxygen: Healing, Brain Health, and Longevity

How breathing pure oxygen under elevated pressure accelerates wound healing, supports brain recovery, and may slow cellular aging

Hyperbaric oxygen therapy (HBOT) involves breathing 100% pure oxygen inside a pressurized chamber at 1.5 to 3 times normal atmospheric pressure. Under these conditions, oxygen dissolves directly into the blood plasma — not just red blood cells — dramatically raising the amount of oxygen delivered to tissues. This has well-established effects on wound healing, particularly for diabetic foot ulcers, where a meta-analysis of 14 controlled trials found HBOT significantly improved complete healing rates and reduced major amputation risk. [1] More recently, research has expanded into brain injury recovery, inflammatory conditions, and even cellular aging, where a 2020 trial found that repeated HBOT sessions lengthened telomeres — the protective caps on chromosomes that shorten with age — by more than 20% in immune cells. [3]

How Hyperbaric Oxygen Works

At sea level, hemoglobin in red blood cells carries about 97% of the oxygen your blood transports, leaving very little dissolved in plasma. Under hyperbaric conditions — inside a pressurized chamber breathing pure oxygen — Henry's Law dictates that gas dissolves into liquid in proportion to its partial pressure. At 2–3 atmospheres of pure oxygen, enough O₂ dissolves directly into blood plasma to sustain tissue metabolism even without functioning red blood cells. This is the clinical reason HBOT was originally developed: it can oxygenate tissue that would otherwise be starved due to poor circulation or vessel damage.

The elevated oxygen environment triggers several downstream effects:

Angiogenesis. HBOT stimulates the growth of new blood vessels (angiogenesis) through upregulation of vascular endothelial growth factor (VEGF). This is central to its wound-healing effect — damaged tissue that lacks adequate blood supply gets a regenerative push.

Antimicrobial action. High tissue oxygen levels are directly toxic to many anaerobic bacteria and potentiate the ability of white blood cells to kill pathogens. This is why HBOT is a standard treatment for gas gangrene and necrotizing fasciitis in conventional medicine.

Reduced inflammation. Repeated HBOT sessions appear to modulate the inflammatory response, downregulating pro-inflammatory cytokines. This mechanism may explain effects seen in conditions like fibromyalgia and TBI recovery that go beyond simple oxygenation.

Mitochondrial and cellular effects. The hyperoxic environment during HBOT and the relative hypoxia that follows (when the body returns to normal pressure) creates an oscillating oxygen signal. Research suggests this intermittent hyperoxia-reoxygenation pattern activates repair pathways including those governing telomere maintenance and the clearance of senescent cells. [3]

Wound Healing: The Established Use

The most solid clinical evidence for HBOT is in wound healing, particularly for non-healing diabetic foot ulcers. These ulcers develop when chronically elevated blood sugar damages blood vessels and nerves in the feet, creating tissue that is poorly oxygenated and resistant to normal healing. A 2021 systematic review and meta-analysis pooled 14 controlled trials involving 768 participants. HBOT significantly improved rates of complete ulcer healing (odds ratio 0.29, meaning much higher healing rates in the HBOT group) and reduced the risk of major amputation (relative risk 0.60, a 40% reduction). [1] HBOT for diabetic foot wounds is now recognized by Medicare and many insurance systems as a standard-of-care adjunct treatment.

Brain Injury and Cognition

A 2020 randomized controlled trial by Harch et al. assigned 63 civilians and veterans with mild traumatic brain injury (TBI) and persistent post-concussion syndrome to either 40 HBOT sessions (at 1.5 atmospheres, 60 minutes per session, five days per week) or a sham control condition, with crossover. The HBOT group showed statistically significant improvements in neurobehavioral symptom scores, memory, depression, anxiety, PTSD symptoms, sleep quality, and overall quality of life. The crossover group achieved near-identical improvements after crossing to HBOT. [2]

A 2022 systematic review of 10 studies (6 RCTs, 4 pilot studies) on HBOT for cognitive impairment after TBI found generally positive but heterogeneous results, calling for larger, more standardized trials before definitive conclusions can be drawn. [6] The evidence is promising but not yet definitive: HBOT appears to help in TBI recovery, but optimal protocols (pressure, session number, timing after injury) are still being established.

Telomeres and Cellular Aging

Perhaps the most striking recent finding came from a 2020 Israeli prospective trial by Hachmo et al. involving 35 healthy adults aged 64 and older. Participants underwent 60 daily HBOT sessions. Blood samples were collected at baseline, after 30 sessions, after 60 sessions, and 1–2 weeks after the final session. Telomere length — measured in multiple immune cell types including T helper, T cytotoxic, NK, and B cells — increased by over 20% across cell types, with B cells showing gains of 26–38%. Simultaneously, the proportion of senescent T cells (aged, non-functional immune cells) decreased by 37% (T helper cells) and 11% (T cytotoxic cells). [3]

These findings are biologically significant because telomere shortening is a well-established marker of cellular aging, and senescent cell accumulation drives chronic inflammation and tissue dysfunction. However, this was a single uncontrolled trial — no sham group, no randomization — and the same research group (at Shamir Medical Center, Israel) is behind several HBOT publications, which warrants independent replication before strong conclusions are drawn.

Inflammation and Fibromyalgia

A 2024 RCT compared 60 HBOT sessions against FDA-approved medications (pregabalin and duloxetine) in 48 women with fibromyalgia related to childhood trauma. HBOT outperformed pharmacological treatment on fibromyalgia impact questionnaire scores, with a Cohen's d effect size of −1.27 — a large effect by clinical standards. Brain imaging showed increased activity in prefrontal and temporal regions correlating with symptom improvement. [4] This is a well-designed RCT with meaningful results, though the specific population (fibromyalgia with trauma history) limits how broadly the findings can be generalized.

Athletic Recovery

The evidence for HBOT in athletic performance and recovery is weaker. A 2021 systematic review and meta-analysis of 10 studies found no statistically significant effect of pre-exercise or post-exercise HBOT on either performance or recovery metrics. Intra-exercise HBOT showed some signal in individual studies, but there was insufficient data for a pooled analysis. [5] For general athletic recovery, HBOT is not currently supported by strong evidence — other modalities like cold water immersion or sleep have better-established evidence bases.

Practical Considerations

HBOT is administered in two settings: multiplace chambers (large rooms accommodating multiple people, used in hospitals) and monoplace chambers (single-person tubes, used in clinics and increasingly in home settings). Sessions typically run 60–90 minutes at 1.5–3 ATA (atmospheres absolute), with most therapeutic protocols involving 20–40 sessions.

Mild HBOT (1.3–1.5 ATA) is increasingly offered at wellness centers without a prescription and is generally considered low-risk. Higher-pressure clinical HBOT (2–3 ATA) is used medically and carries small risks of oxygen toxicity (rare, manifesting as seizures at very high doses) and barotrauma (pressure injury to ears or sinuses).

See our red light therapy page for a related photobiomodulation approach to cellular energy, and our float tanks page for another sensory therapy with well-established research.

Evidence Review

Wound Healing: Sharma et al. 2021 (PMID 33500533)

This systematic review and meta-analysis in Scientific Reports is the most comprehensive pooled analysis of HBOT for diabetic foot ulcers. Fourteen controlled clinical trials totaling 768 participants met inclusion criteria. The primary endpoint — complete ulcer healing — showed a significant advantage for HBOT over control (odds ratio 0.29, 95% CI 0.14–0.61), indicating participants receiving HBOT had substantially higher rates of complete healing. The secondary endpoint — major amputation — was also significantly reduced (RR 0.60, 95% CI 0.39–0.92), representing a 40% relative risk reduction. Minor amputation rates and ulcer surface area reduction did not differ significantly between groups.

The authors note considerable methodological heterogeneity across included trials — differences in HBOT protocols, wound classification, follow-up duration, and control conditions — limiting the precision of pooled estimates. Nevertheless, the direction and magnitude of effect across trials is consistent, supporting HBOT as an effective adjunct for diabetic foot ulcers when added to standard wound care. This indication has sufficient evidence to be covered by Medicare (it is FDA-cleared for diabetic foot wounds, class III soft tissue radionecrosis, and several other conditions).

TBI Recovery: Harch et al. 2020 (PMID 32189664)

This RCT in Medical Gas Research used a crossover design: participants were randomized to immediate HBOT (40 sessions at 1.5 ATA / 150 kPa, 60 minutes/session, 5 days/week) followed by a 3-month observational phase, or to a wait-list control followed by HBOT. Sixty-three participants enrolled; 50 completed the primary outcome assessment. The population included both military personnel and civilians with mild TBI and persistent post-concussion syndrome lasting more than three months.

Primary and secondary outcomes covered neurobehavioral symptoms (Neurobehavioral Symptom Inventory), memory (Repeatable Battery for Assessment of Neuropsychological Status), depression and PTSD (PCL-17), quality of life (SF-36), and sleep (Pittsburgh Sleep Quality Index). The HBOT group showed statistically significant improvements across all major domains after 40 sessions. When the control group subsequently crossed over to HBOT, they achieved essentially identical improvements, strengthening the causal inference. The crossover design also serves as partial replication within the same study.

Limitations include that blinding was imperfect (participants were aware of group assignment in a crossover trial), and the 1.5 ATA protocol is lower pressure than some earlier negative TBI trials, which may explain why this study found benefits where some earlier higher-pressure protocols did not.

Telomere Lengthening: Hachmo et al. 2020 (PMID 33206062)

Published in Aging (Albany NY), this prospective trial measured telomere length and immune senescence in 35 healthy older adults (mean age ~65) before, during (session 30), and after (session 60 and 1–2 weeks post-treatment) a 60-session HBOT protocol at 2 ATA with 100% oxygen, 90-minute sessions, 5 days per week for 12 weeks. Telomere length was measured in peripheral blood mononuclear cells sorted by cell type (CD4+ T helper, CD8+ T cytotoxic, CD19+ B, CD56+ NK cells).

Telomere length increased significantly in all measured cell types. The magnitude was large: T helper cells +25.7%, T cytotoxic cells +29.7%, NK cells +20.5%, B cells +37.6% from baseline to post-treatment. Senescent T helper cells decreased by 37.3% and senescent T cytotoxic cells by 10.96% (both p < 0.05). The proposed mechanism involves the intermittent hyperoxia-reoxygenation cycles acting as an epigenetic signal activating telomerase or telomere-repair pathways.

Critical limitations: no control group, single research site (Shamir Medical Center/Tel Aviv University), relatively small sample of 35, and the same group has produced most of the positive HBOT longevity literature. Independent replication is needed before this finding can be considered established. However, the biological plausibility is strong and the effect sizes are striking enough to warrant continued investigation.

Fibromyalgia: Boussi-Gross et al. 2024 (PMID 38773296)

This randomized controlled trial compared 60 HBOT sessions against standard pharmacological treatment (pregabalin and/or duloxetine) over 8 weeks in 48 women with fibromyalgia syndrome specifically associated with childhood sexual abuse. HBOT protocol: 2 ATA, 90 minutes/session, 5 days/week. The primary outcome was the Fibromyalgia Impact Questionnaire-Revised (FIQR).

HBOT significantly outperformed medication on FIQR total score (Cohen's d = −1.27, a large effect). Secondary outcomes including emotional symptoms, cognitive function, and functional disability also favored HBOT. Single photon emission computed tomography (SPECT) brain imaging identified increased perfusion in prefrontal and temporal brain regions in HBOT responders, correlating with functional improvement. This neuroimaging component is unusual in fibromyalgia trials and suggests HBOT may work through central nervous system mechanisms rather than purely peripheral inflammation.

Key caveats: the specific patient population (trauma-associated fibromyalgia) may not generalize to all fibromyalgia subtypes. The same research group has conducted most high-profile HBOT studies, raising questions about publication bias and site-specific effects. An independent multicenter RCT would substantially strengthen confidence in these findings.

Athletic Recovery: Huang et al. 2021 (PMID 34887780)

This systematic review and meta-analysis in Frontiers in Physiology searched for RCTs and controlled trials on HBOT for athletic performance and recovery. Ten studies met inclusion criteria (166 participants across all studies, with 69 available for quantitative pooling on specific outcomes). Outcomes examined included VO₂max, maximal strength, blood lactate clearance, muscle soreness, and return-to-play time.

Pre-exercise and post-exercise HBOT showed no statistically significant effects on any primary performance or recovery outcome (p > 0.05 across pooled analyses). Heterogeneity was moderate to high (I² 30–65% across analyses), reflecting variation in HBOT protocols, timing, and participant populations across studies. Intra-exercise HBOT — breathing oxygen during activity inside a pressurized environment — showed some positive signals on muscle endurance in individual studies but could not be pooled due to insufficient data. The authors called for standardized protocols in future research. For athletes seeking evidence-based recovery tools, cold water immersion, sleep, and adequate nutrition have stronger evidence than HBOT at present.

Overall Evidence Assessment

HBOT has a well-established evidence base for wound healing (Medicare-approved, multiple RCTs) and an emerging evidence base for TBI recovery (positive RCT, systematic review with caveats). The longevity and senescence findings are biologically interesting but require independent replication. Fibromyalgia results are promising from a single research group. Athletic use lacks meaningful support. The safety profile for standard protocols is very good: oxygen toxicity and barotrauma are rare at pressures used in therapeutic settings. Mild HBOT at 1.3 ATA, increasingly used in wellness settings, is even lower risk. The main barrier to access is cost: clinical HBOT sessions typically run $150–300 USD each, and insurance coverage is limited to FDA-approved indications.

References

Efficacy of hyperbaric oxygen therapy for diabetic foot ulcer, a systematic review and meta-analysis of controlled clinical trialsSharma R, Sharma SK, Mudgal SK, Jelly P, Thakur K. Scientific Reports, 2021. PubMed 33500533 →
Hyperbaric oxygen therapy for mild traumatic brain injury persistent postconcussion syndrome: a randomized controlled trialHarch PG, Andrews SR, Rowe CJ, Lischka JR, Townsend MH, Yu Q, Mercante DE. Medical Gas Research, 2020. PubMed 32189664 →
Hyperbaric oxygen therapy increases telomere length and decreases immunosenescence in isolated blood cells: a prospective trialHachmo Y, Hadanny A, Abu Hamed R, Daniel-Kotovsky M, Catalogna M, Fishlev G, Lang E, Polak N, Doenyas K, Friedman M, Zemel Y, Bechor Y, Efrati S. Aging (Albany NY), 2020. PubMed 33206062 →
Hyperbaric oxygen therapy vs. pharmacological intervention in adults with fibromyalgia related to childhood sexual abuse: prospective, randomized clinical trialBoussi-Gross R, Catalogna M, Lang E, Shamai Z, Ablin JN, Aloush V, Doenyas-Barak K, Lorberboym M, Lev-Wiesel R, Efrati S. Scientific Reports, 2024. PubMed 38773296 →
Effects of Pre-, Post- and Intra-Exercise Hyperbaric Oxygen Therapy on Performance and Recovery: A Systematic Review and Meta-AnalysisHuang X, Wang R, Zhang Z, Wang G, Gao B. Frontiers in Physiology, 2021. PubMed 34887780 →
Hyperbaric oxygen therapy for cognitive impairments in patients with traumatic brain injury: A systematic reviewAlashram AR, Padua E, Romagnoli C, Annino G. Applied Neuropsychology: Adult, 2022. PubMed 35213282 →